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In a recent edition of Vascular Health and Risk Management, Kirmizis and 
Chatzidimitriou have published a review article, “Antiatherogenic effects of vitamin E: 
the search for the Holy Grail”.
Beside a general evaluation of the literature on vitamin E and CVD prevention, 
the authors pointed out the possibility that vitamin E therapy may have particular 
efficacy in kidney patients. In this sense, they may represent an elective population 
with high susceptibility to such a secondary prevention effect, that was not identified 
in other cardiovascular (CVD) patient populations studied in the largest randomized 
controlled trials. The SPACE study,1 indeed, provided one of the most striking findings 
in support of this assumption.
The reason for this could be inherent to a defect in the levels and metabolism of 
vitamin E in kidney patients documented in previous studies,2,3 but also in the higher 
demand of vitamin E that these patients may have as a consequence of the exposure 
to chronic inflammation and uremic toxicity. This higher than normal demand of 
vitamin E may translate into a higher need for antioxidant protection, but also of other 
biological functions of this vitamin that include homeostatic effects on genes involved 
in immuno-inflammatory and vascular protection pathways.4
The authors have highlighted the unconventional vitamin E therapy that some 
of these patients follow while treated with extracorporeal hemodialysis therapy 
(HD). This consists of the use of a special biomaterial developed to produce 
hollow-fiber hemodialysesrs that are coated on the blood surface with a layer 
of all-rac-α-tocopherol, ie, the synthetic form of vitamin E that predominates 
in our tissues and body fluids.4,5 These hemodialyser membranes, also known as 
vitamin E-modified membranes, were developed in the 1980s in Japan as cellulosic 
membranes that were introduced in the clinical practice in the early 1990s in Japan 
and then in Europe. The first clinical observation on these innovative membranes 
was published in a peer-reviewed journal on 1997.6 In recent years, this cellulosic 
prototype has been substituted with a new generation of vitamin E-modified 
(or -interactive) membranes that possess the highest depurative and biocompatibility 
standards in HD being produced using a polysulfone-like fiber backbone with an 
advanced filtration geometry. Other than biocompatible, these synthetic membranes 
have now a well characterized antioxidant activity profile that was recent described 
and quantitated in vitro.7
However, this should not lead to consider the antioxidant activity of these 
dialysers as fully available for an antioxidant effect in vivo, during the extracorporeal 
circulation.
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Actually, since from the first researches by us and other 
groups in the late 1990s, it was clear that the clinical effects 
of these membranes could not be explained simply with the 
concept that the chromanols bound to the dialysis membrane 
surface may produce an in vivo scavenging effect on peroxyl 
radicals, ie, producing an antioxidant therapy effect.
In other words, the antioxidant activity as well as the 
other beneficial properties of this vitamin E (bound to the 
dialyser membranes), are probably different from those of 
the vitamin E form introduced with the diet or supplements, 
which is present in the circulation within the lipoprotein 
particles and in the cell membranes.
Thus, the interpretation of possible therapeutic mecha-
nisms by these modified membranes needs more careful 
dissection and further studies aimed to verify underlying 
events. To explain the benefical effects of these membranes 
reported in literature, they have used expressions such as 
“pharmacokinetic factors”, “the type of the α-T molecule 
used”, “form of the drug” or “pharmacokinetic conditions”, 
which are obviously inappropriate in this context and may 
generate confusion in the readers.
In the case of these membranes, indeed, the form of 
vitamin E that should be taken into account is exclusively 
that present in synthetic coating on the blood surface of the 
hollow fiber, ie, all-rac-α-tocopherol, and this vitamin E 
form does not seem to be released even under drastic in vitro 
recirculation conditions.7 Thus, there is no reason to discuss 
clinical effects of vitamin E-modified membrane dialysers 
in terms of “pharmacokinetics”.
As Kirmizis and Chatzidimitriou briefly discussed in 
their review paper, the antioxidation and anti-inflammatory 
protection claimed in several studies on these membranes are 
probably the result of a complex series of effects. Accord-
ing to the available evidence in literature already reviewed 
by us8,9 and others,10 even the previous generations of less 
biocompatible (cellulosic) vitamin E-modified hemodialyser 
membranes were observed to produce a better control of 
antioxidant parameters and lowered oxidative stress mark-
ers,11–14 but at the same time these membranes were found to 
provide a better control of leukocyte activation and apoptotic 
death,8,15,16 of erythrocyte integrity and lifespan,17,18,a and to 
afford higher protection of low-density lipoproteins and endo-
thelial cells.19,20 Probably, the interaction of all these effects 
is responsible for the improved CVD outcome observed in 
a series of promising small clinical studies that examined 
aortic calcifications,21 carotid atherosclerosis17,22 and the nitric 
oxide-dependent vasodilation response during HD.23
In conclusion, it is my belief that all these effects and the 
efforts made by the authors to explain them in this review 
paper can be summarized in the concept of “superior biocom-
patibility” that these vitamin E-modified membranes may have 
with respect to several other dialyser membranes particularly 
in the recent interactive polysulfone-based version.
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We thank Dr Galli for his interest in our paper1 and his useful 
remarks. We also appreciate his encouraging comments on 
our concerns regarding the possibility that the benefits from 
the α-T supplementation treatment might be accentuated 
particularly in special patient populations, such as diabetics 
or end-stage renal disease patients, ie, patients with high 
degrees of both oxidative stress and chronic inflammation. 
Furthermore, in accordance to the comments on vitamin 
E-modified membrane dialyzers pointed out in the letter, 
we ourselves have stated in our paper the importance of 
in situ action of the membrane-bound α-Τ, arguing that 
“the beneficial effects of the membrane-bound α-Τ probably 
take place through the protection it provides to circulating 
leukocytes against their repeated activation by the otherwise 
bioincompatible synthetic dialysis membrane and the abate-
ment of the inflammatory reaction might secondarily lead to 
the antioxidative effects of α-Τ”. Therefore, in order to avoid 
any confusion, we would like to underline that we agree that 
any discussion on “pharmacokinetics” refers exclusively to 
α-Τ supplementation studies and does not apply in vitamin 
E-modified membrane dialyzers.
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